Evidence map›Paper›PMID 30145772›Full record

ArticleInfection2019

Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.

Hortensia Álvarez, Ana Mariño, Nieves Valcarce, Jesús García-González, Helena Díaz-Cambre, Josep M Llibre

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hortensia ÁlvarezInfectious Diseases Unit, Internal Medicine Department, University Hospital of Ferrol, Avda. da Residencia, s/n, 15405, Ferrol, A Coruña, Spain. hortensia.alvarez.diaz@sergas.es.
Ana MariñoInfectious Diseases Unit, Internal Medicine Department, University Hospital of Ferrol, Avda. da Residencia, s/n, 15405, Ferrol, A Coruña, Spain.
Nieves ValcarceHospital Pharmacy, University Hospital of Ferrol, A Coruña, Spain.
Jesús García-GonzálezPsychiatry Department, University Hospital of Ferrol, A Coruña, Spain.
Helena Díaz-CambreNephrology Department, University Hospital of Ferrol, A Coruña, Spain.
Josep M LlibreInfectious Diseases and "Fight AIDS" Foundation, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionData are lacking regarding overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF). MATERIAL AND

methodsWe present the first report of suicidal attempt with E/C/F/TAF in a Human Immunodeficiency Virus-infected subject.

resultsA reversible acute renal failure with no proximal tubulopathy and neuropsychiatric issues are discussed. E/C/F/TAF withdrawal resulted in favourable renal and neuropsychiatric outcomes. The suicide attempt seemed unrelated to the integrase strand transfer inhibitor, being evenly explained within the context of stressful personal conflicts.

conclusionA suicidal attempt with an E/C/F/TAF overdose in an HIV-infected patient, resulted in a favourable outcome from a renal and neuropsychiatric standpoint.

Indexed as

Suicide, AttemptedAdenineAlanineAnti-HIV AgentsCobicistatDrug CombinationsDrug OverdoseEmtricitabineHIV InfectionsHumansMaleMiddle AgedQuinolonesRenal InsufficiencyTenofovirAdenineAlanineAnti-HIV AgentsCobicistatDrug CombinationselvitegravirEmtricitabineQuinolonesTenofovirtenofovir alafenamideElvitegravir/cobicistat/emtricitabine/tenofovir alafenamideOverdoseSuicide attempt

Identifiers

PMID30145772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.